Intellectual Property & Proprietary Rights



Issued US Patents


US #6,153,182

Compositions and doses of lymphotactin given in conjunction with vaccines to provide improved immune response

US #6,479,047

Methods of lymphotactin use as an adjuvant to boost mucosal immune responses to a vaccine antigen

US #7,919,083

Antibodies or the use of antibodies directed against CCL25 and CCR9 that propagate melanoma growth, migration, and/or invasion.

US #7,964,194

Antibodies or the use of antibodies directed against CXCL10 that mediate inflammation

US #8,097,250

Antibodies or the use of antibodies directed against CXCL13 and CXCR5 that propagate melanoma growth, migration, and/or invasion

US #8,231,907

Methods of milling nanoparticles containing a biologically active agent, at least one biopolymer, where coating contains at least one polymer or ligand

US #8,318,170

Antibodies or the use of antibodies directed against CXCL9 and CXCL11 that mediate inflammation

US #8,512,701

Antibodies or the use of antibodies directed against CXCL13 and CXCR5 to prevent and treat cancer and cancer cell migration.

US #8,541,564

Novel chemokine-immunoglobulin fusion polypeptides and uses to treat chemokine receptor-mediated disorders, including cancer and inflammatory disorders.

US #8,580,261

Antibodies or the use of antibodies directed against CCL25 that mediate inflammation

US #8,563,476

Antibodies or the use of antibodies directed against chemokines (CXCL9, CXCL10, CXCL11, and CXCL13) and chemokine receptors (CXCR3 and CXCR5) as agents against inflammatory disorders

US #8,568,784

Compositions comprising milled nanoparticles containing an anti-cancer agent, polyethylene glycol, and starch, cellulose, collagen, lactose, or alginate

US #8,658,377

Antibodies or the use of antibodies directed against CCL25 and CCR9 to detect cancer and metastasis

US #8,796,422

CCL2-immunoglobulin fusion polypeptides and conjugates for targeted treatment of CCR2-and CCR4-mediated disorders

US #8,962,030

Methods of formulating a pharmaceutical composition using milled nanoparticles of precise size containing an anti-cancer agent, polyethylene glycol, and starch, cellulose, collagen, lactose, or alginate

US #8,987,210

Chemokine-immunoglobulin fusion polypeptides and chemokine-polymer conjugates

US #9,233,120

Antibodies or the use of antibodies directed against CCL25 and CCR9 to prevent and treat cancer and cancer cell migration

US #9,249,204

CXCL13-immunoglobulin fusion polypeptides and conjugates for targeted treatment of CXCR5-mediated disorders.

US #9,493,531

CCL18-immunoglobulin fusion polypeptides and conjugates for targeted treatment of PITPNM3-, GPR30-, and CCR8 -mediated disorders.

US #9,783,588

CXCL12-immunoglobulin fusion polypeptides and conjugates for targeted treatment of CXCR4-mediated disorders.


Foreign Patent Applications

CN ZL201280032847.7

Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof

EP2652508B1

The use of anti-cxcl13 and anti-cxcr5 antibodies for the treatment or detection of cancer

US20170280712A1 Notice of Allowance (6/28/2018)

Compositions and methods nanoformulations for plants